Kesmalea Therapeutics Appoints Robert Johnson As Chief Executive Officer

Nov 07, 2024•8 months ago

Position

Chief Executive Officer

Company

Kesmalea Therapeutics

Robert Johnson

LondonBiopharmaTherapeuticsBiotechnologyHealth Care

Description

Kesmalea Therapeutics has announced the appointment of Robert Johnson as its Chief Executive Officer. Johnson will lead the company’s growth phase, focusing on a new small molecule approach to targeted protein degradation. The company aims to address the challenges associated with large protein degraders and broaden the applications of targeted protein degradation into important disease areas.

Company Information

Company

Kesmalea Therapeutics

Location

London, England, United Kingdom

About

Kesmalea Therapeutics is a biopharmaceutical company focused on developing a pipeline of novel therapeutics based on transforming large protein degraders into small molecules. Their proprietary technology, SELFTAC®, aims to address challenges in targeted protein degradation to enable oral dosing and central nervous system penetration.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Robert hidden